Randomized Controlled-trial to Evaluate Safety, Immunogenicity and Efficacy of a Vaccine Composed of a Recombinant S1 Antigen for Prevention of Covid-19 in Adults Previously Fully Immunized With Other Vaccines

Randomized controlled trial to evaluate safety, immunogenicity and efficacy of three different doses (10, 25 and 50 mcg) of a novel vaccine compared with placebo in adult volunteers previously immunized against Covid-19 with other vaccines [Corona Vac (Sinovac), ChAdOx1 (AZ 1222, Astra Zeneca) or Ad26.Co2.S (Janssen)].

开始日期2021-11-01

申办/合作机构

Hospital do Coração

[+1]

100 项与 Recombinant S1 antigen vaccine(Farmacore Biotecnologia Ltda) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant S1 antigen vaccine(Farmacore Biotecnologia Ltda) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant S1 antigen vaccine(Farmacore Biotecnologia Ltda) 相关的专利（医药）

登录后查看更多信息

项与 Recombinant S1 antigen vaccine(Farmacore Biotecnologia Ltda) 相关的文献（医药）

2023-05-09·Vaccines

Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein.

Article

作者: Fan, Shengtao ; Li, Dandan ; Liao, Yun ; Li, Hangwen ; Cui, Pingfang ; Zhao, Heng ; Jiang, Guorun ; Zhang, Ying ; Yu, Li ; Li, Qihan

(1) Background: As the COVID-19 pandemic enters its fourth year, it continues to cause significant morbidity and mortality worldwide. Although various vaccines have been approved and the use of homologous or heterologous boost doses is widely promoted, the impact of vaccine antigen basis, forms, dosages, and administration routes on the duration and spectrum of vaccine-induced immunity against variants remains incompletely understood. (2) Methods: In this study, we investigated the effects of combining a full-length spike mRNA vaccine with a recombinant S1 protein vaccine, using intradermal/intramuscular, homologous/heterologous, and high/low dosage immunization strategies. (3) Results: Over a period of seven months, vaccination with a mutant recombinant S1 protein vaccine based on the full-length spike mRNA vaccine maintained a broadly stable humoral immunity against the wild-type strain, a partially attenuated but broader-spectrum immunity against variant strains, and a comparable level of cellular immunity across all tested strains. Furthermore, intradermal vaccination enhanced the heterologous boosting of the protein vaccine based on the mRNA vaccine. (4) Conclusions: This study provides valuable insights into optimizing vaccination strategies to address the ongoing challenges posed by emerging SARS-CoV-2 variants.

2021-01-01·Emerging Microbes & Infections2区 · 医学

A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques

2区 · 医学

ArticleOA

作者: Hu, Guangnan ; Duan, Jinmei ; Yang, Yaoyun ; Che, Yanchun ; Hu, Zhengrong ; Xiao, Hongjian ; He, Zhanlong ; Yao, Yueting ; Li, Haiwei ; Liu, Shuying ; Liu, Xiaojuan ; Ding, Chen ; Wang, Shixia ; Li, Yadong ; Zhang, Heng ; Liu, Longding ; Li, Yuzhong ; Li, Zhihua ; Cun, Wei ; Li, Qihan ; Bi, Yanwei ; Lu, Shan ; Yang, Jianbo

The current study aims to develop a safe and highly immunogenic COVID-19 vaccine. The novel combination of a DNA vaccine encoding the full-length Spike (S) protein of SARS-CoV-2 and a recombinant S1 protein vaccine induced high level neutralizing antibody and T cell immune responses in both small and large animal models. More significantly, the co-delivery of DNA and protein components at the same time elicited full protection against intratracheal challenge of SARS-CoV-2 viruses in immunized rhesus macaques. As both DNA and protein vaccines have been proven safe in previous human studies, and DNA vaccines are capable of eliciting germinal center B cell development, which is critical for high-affinity memory B cell responses, the DNA and protein co-delivery vaccine approach has great potential to serve as a safe and effective approach to develop COVID-19 vaccines that provide long-term protection.

2019-01-01·Emerging Microbes & Infections

Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein

Article

作者: van Dieren, Brenda ; Bosch, Berend-Jan ; Vergara-Alert, Júlia ; Haagmans, Bart L. ; Bensaid, Albert ; Okba, Nisreen M. A. ; Te, Nigeer ; Segalés, Joaquim ; Rodon, Jordi

The ongoing Middle East respiratory syndrome coronavirus (MERS-CoV) outbreaks pose a worldwide public health threat. Blocking MERS-CoV zoonotic transmission from dromedary camels, the animal reservoir, could potentially reduce the number of primary human cases. Here we report MERS-CoV transmission from experimentally infected llamas to naïve animals. Directly inoculated llamas shed virus for at least 6 days and could infect all in-contact naïve animals 4-5 days after exposure. With the aim to block virus transmission, we examined the efficacy of a recombinant spike S1-protein vaccine. In contrast to naïve animals, in-contact vaccinated llamas did not shed infectious virus upon exposure to directly inoculated llamas, consistent with the induction of strong virus neutralizing antibody responses. Our data provide further evidence that vaccination of the reservoir host may impede MERS-CoV zoonotic transmission to humans.

100 项与 Recombinant S1 antigen vaccine(Farmacore Biotecnologia Ltda) 相关的药物交易

登录后查看更多信息